Breakdown |
---|
Income Statement |
Total Revenue |
Gross Profit |
EBITDA |
Net Income |
Balance Sheet |
Total Assets |
Cash, Cash Equivalents and Short-Term Investments |
Total Debt |
Total Liabilities |
Stockholders Equity |
Cash Flow |
Free Cash Flow |
Operating Cash Flow |
Investing Cash Flow |
Financing Cash Flow |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $99.55M | -2.42 | -38.74% | ― | 1071.91% | -27.61% | |
49 Neutral | $79.85M | ― | -110.94% | ― | -9.61% | 20.36% | |
44 Neutral | $25.40M | -0.44 | ― | ― | ― | 32.57% | |
43 Neutral | $22.15M | -1.17 | ― | ― | ― | 12.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
MindWalk Holdings Corp. announced its financial results for the three months ended July 31, 2025, highlighting its strategic expansion and organic revenue growth in the biologics and Contract Research Organizations (CRO) space. The company has achieved growth through market penetration, service diversification, and strategic expansion in Europe, supported by investments in research and development. MindWalk’s unique integration of in silico and wet lab technologies positions it as a leader in the industry, offering innovative solutions and a comprehensive suite of services to its partners.
On September 15, 2025, MindWalk Holdings Corp. reported record quarterly revenue of $7.6 million, marking a 45% year-over-year growth, with significant margin expansion and reduced losses. The company completed the divestiture of its Netherlands operations, generating $16.1 million in proceeds, which strengthened its balance sheet and allowed a sharper focus on AI-driven initiatives. The rebranding to MindWalk, uniting various entities under one identity, and advancements in their dengue vaccine program and LensAI validation, underscore their strategic shift towards becoming a fully integrated BioIntelligence company.